HOLMLUND JON T 4

4 · Galera Therapeutics, Inc. · Filed May 12, 2020

Form 4

Period: 2020-05-08

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2020-05-08$1.07/sh+5,102$5,459→ 5,102 total
Sale
Common Stock
2020-05-08$12.00/sh−5,102$61,224→ 0 total
Exercise/Conversion
Common Stock
2020-05-11$1.07/sh+185$198→ 185 total
Sale
Common Stock
2020-05-11$12.00/sh−185$2,220→ 0 total
Exercise/Conversion
Common Stock
2020-05-12$1.07/sh+671$718→ 671 total
Sale
Common Stock
2020-05-12$12.00/sh−671$8,052→ 0 total
Exercise/Conversion
Stock Option
2020-05-08−5,102→ 8,695 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (5,102 underlying)
Exercise/Conversion
Stock Option
2020-05-11−185→ 8,510 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (185 underlying)
Exercise/Conversion
Stock Option
2020-05-12−671→ 7,839 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (671 underlying)

Footnotes (3)

[F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2019.
[F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.00 to $12.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The option has fully vested and is currently exercisable.

Documents

1 file